Oncogenic activity and cellular functionality of melanoma associated antigen A3

Paula Schäfer; Themistoklis Paraschiakos; Sabine Windhorst

doi:10.1016/j.bcp.2021.114700

Oncogenic activity and cellular functionality of melanoma associated antigen A3

Standard

Oncogenic activity and cellular functionality of melanoma associated antigen A3. / Schäfer, Paula; Paraschiakos, Themistoklis; Windhorst, Sabine.

in: BIOCHEM PHARMACOL, Jahrgang 192, 114700, 10.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Schäfer, P, Paraschiakos, T & Windhorst, S 2021, 'Oncogenic activity and cellular functionality of melanoma associated antigen A3', BIOCHEM PHARMACOL, Jg. 192, 114700. https://doi.org/10.1016/j.bcp.2021.114700

APA

Schäfer, P., Paraschiakos, T., & Windhorst, S. (2021). Oncogenic activity and cellular functionality of melanoma associated antigen A3. BIOCHEM PHARMACOL, 192, [114700]. https://doi.org/10.1016/j.bcp.2021.114700

Vancouver

Schäfer P, Paraschiakos T, Windhorst S. Oncogenic activity and cellular functionality of melanoma associated antigen A3. BIOCHEM PHARMACOL. 2021 Okt;192. 114700. https://doi.org/10.1016/j.bcp.2021.114700

Bibtex

@article{cf1695ee13ec442584e5f64ab36ac961,

title = "Oncogenic activity and cellular functionality of melanoma associated antigen A3",

abstract = "Cancer testis antigen Melanoma associated antigen A3 (MAGE-A3) has been subject of research for many years. Being expressed in various tumor types and influencing proliferation, metastasis, and tumor pathogenicity, MAGE-A3 is an attractive target for cancer therapy, particularly because in healthy tissues, MAGE-A3 is only expressed in testes and placenta. MAGE-A3 acts as a cellular master regulator by stimulating E3 ubiquitin ligase tripartite motif-containing protein 28 (TRIM28), resulting in regulation of various cellular targets. These include tumor suppressor protein p53 and cellular energy sensor AMP-activated protein kinase (AMPK). The restricted expression of MAGE-A3 in tumor cells makes MAGE-A3 an attractive target for vaccine-based immune therapy. However, although phase I and phase II clinical trials involving MAGE-A3-specific immunotherapeutic interventions were promising, large phase III studies failed. This article gives an overview about the role of MAGE-A3 as a cellular master switch and discusses approaches to improve MAGE-A3-based immunotherapies.",

keywords = "AMP-Activated Protein Kinases/immunology, Animals, Antigens, Neoplasm/chemistry, Carcinogenesis/immunology, Humans, Immunotherapy/methods, Neoplasm Proteins/chemistry, Neoplasms/immunology, Neoplastic Cells, Circulating/immunology, Protein Structure, Tertiary",

author = "Paula Sch{\"a}fer and Themistoklis Paraschiakos and Sabine Windhorst",

year = "2021",

month = oct,

doi = "10.1016/j.bcp.2021.114700",

language = "English",

volume = "192",

journal = "BIOCHEM PHARMACOL",

issn = "0006-2952",

publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Oncogenic activity and cellular functionality of melanoma associated antigen A3

AU - Schäfer, Paula

AU - Paraschiakos, Themistoklis

AU - Windhorst, Sabine

PY - 2021/10

Y1 - 2021/10

N2 - Cancer testis antigen Melanoma associated antigen A3 (MAGE-A3) has been subject of research for many years. Being expressed in various tumor types and influencing proliferation, metastasis, and tumor pathogenicity, MAGE-A3 is an attractive target for cancer therapy, particularly because in healthy tissues, MAGE-A3 is only expressed in testes and placenta. MAGE-A3 acts as a cellular master regulator by stimulating E3 ubiquitin ligase tripartite motif-containing protein 28 (TRIM28), resulting in regulation of various cellular targets. These include tumor suppressor protein p53 and cellular energy sensor AMP-activated protein kinase (AMPK). The restricted expression of MAGE-A3 in tumor cells makes MAGE-A3 an attractive target for vaccine-based immune therapy. However, although phase I and phase II clinical trials involving MAGE-A3-specific immunotherapeutic interventions were promising, large phase III studies failed. This article gives an overview about the role of MAGE-A3 as a cellular master switch and discusses approaches to improve MAGE-A3-based immunotherapies.

AB - Cancer testis antigen Melanoma associated antigen A3 (MAGE-A3) has been subject of research for many years. Being expressed in various tumor types and influencing proliferation, metastasis, and tumor pathogenicity, MAGE-A3 is an attractive target for cancer therapy, particularly because in healthy tissues, MAGE-A3 is only expressed in testes and placenta. MAGE-A3 acts as a cellular master regulator by stimulating E3 ubiquitin ligase tripartite motif-containing protein 28 (TRIM28), resulting in regulation of various cellular targets. These include tumor suppressor protein p53 and cellular energy sensor AMP-activated protein kinase (AMPK). The restricted expression of MAGE-A3 in tumor cells makes MAGE-A3 an attractive target for vaccine-based immune therapy. However, although phase I and phase II clinical trials involving MAGE-A3-specific immunotherapeutic interventions were promising, large phase III studies failed. This article gives an overview about the role of MAGE-A3 as a cellular master switch and discusses approaches to improve MAGE-A3-based immunotherapies.

KW - AMP-Activated Protein Kinases/immunology

KW - Animals

KW - Antigens, Neoplasm/chemistry

KW - Carcinogenesis/immunology

KW - Humans

KW - Immunotherapy/methods

KW - Neoplasm Proteins/chemistry

KW - Neoplasms/immunology

KW - Neoplastic Cells, Circulating/immunology

KW - Protein Structure, Tertiary

U2 - 10.1016/j.bcp.2021.114700

DO - 10.1016/j.bcp.2021.114700

M3 - SCORING: Review article

C2 - 34303709

VL - 192

JO - BIOCHEM PHARMACOL

JF - BIOCHEM PHARMACOL

SN - 0006-2952

M1 - 114700

ER -